Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotypic switching as a non-genetic mechanism of resistance predicts antibody therapy regimens

7 Mar 2024

Abstract excerpt

Despite the specificity and effectiveness of antibody therapy, resistance to treatment remains a major barrier for their broad clinical applications. While genetic mutations are known to be critical, the impact of non-genetic mechanisms, such as epigenetic changes and phenotypic adaptations, on resistance to antibody-dependent cellular cytotoxicity (ADCC) is not fully understood. Our study investigated the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38544569
DOI: 10.1016/j.isci.2024.109450

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotypic switching as a non-genetic mechanism of resistance predicts antibody therapy regimensPMID 38544569Read ↗

Understanding the role of phenotypic switching in cancer drug resistance.Semantic proximity Read ↗

Phenotypic Plasticity, Non-genetic Mechanisms, and Immune Drug Resistance in Cancer.Semantic proximity Read ↗

Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistanceSemantic proximity Read ↗

Mutational processes impact the evolution of anti-EGFR antibody resistance in colorectal cancerSemantic proximity Read ↗

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent EvolutionSemantic proximity Read ↗

Emerging role of tumor cell plasticity in modifying therapeutic responseSemantic proximity Read ↗

Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration StrategiesSemantic proximity Read ↗

Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures.Semantic proximity Read ↗

The role of memory in non-genetic inheritance and its impact on cancer treatment resistanceSemantic proximity Read ↗

Genetic and non‐genetic drug resistance: Darwin or Lamarck?Semantic proximity Read ↗

Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation.Semantic proximity Read ↗

Integrating mutational and nonmutational mechanisms of acquired therapy resistance within the Darwinian paradigm.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.